NZ710744A - Methods for increasing immunoglobulin a levels - Google Patents
Methods for increasing immunoglobulin a levelsInfo
- Publication number
- NZ710744A NZ710744A NZ710744A NZ71074414A NZ710744A NZ 710744 A NZ710744 A NZ 710744A NZ 710744 A NZ710744 A NZ 710744A NZ 71074414 A NZ71074414 A NZ 71074414A NZ 710744 A NZ710744 A NZ 710744A
- Authority
- NZ
- New Zealand
- Prior art keywords
- levels
- methods
- increasing immunoglobulin
- immunoglobulin
- increasing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759108P | 2013-01-31 | 2013-01-31 | |
| PCT/US2014/014107 WO2014121053A1 (en) | 2013-01-31 | 2014-01-31 | Methods for increasing immunoglobulin a levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ710744A true NZ710744A (en) | 2020-07-31 |
Family
ID=50102273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ710744A NZ710744A (en) | 2013-01-31 | 2014-01-31 | Methods for increasing immunoglobulin a levels |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9790271B2 (https=) |
| EP (1) | EP2951204B1 (https=) |
| JP (1) | JP6363623B2 (https=) |
| KR (1) | KR102176962B1 (https=) |
| CN (1) | CN105408355A (https=) |
| AU (1) | AU2014212206B2 (https=) |
| CA (1) | CA2899344C (https=) |
| NZ (1) | NZ710744A (https=) |
| WO (1) | WO2014121053A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2647823T3 (es) | 2009-05-08 | 2017-12-26 | Vaccinex, Inc. | Anticuerpos anti-CD100 y métodos de uso de los mismos |
| AU2011295902B2 (en) | 2010-09-02 | 2014-12-04 | Vaccinex, Inc. | Anti-CXCL13 antibodies and methods of using the same |
| BR112014008885B1 (pt) | 2011-10-11 | 2021-02-17 | Vaccinex, Inc | uso de um anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à semaforina-4d para diminuir permeabilidade da barreira hematoencefálica (bbb) em um indivíduo com permeabilidade da bbb aumentada e um transtorno neuroinflamatório |
| NZ629828A (en) | 2012-03-02 | 2017-05-26 | Vaccinex Inc | Methods for the treatment of b cell-mediated inflammatory diseases |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| MX377858B (es) | 2013-06-25 | 2025-03-11 | Vaccinex Inc | Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos. |
| IL262232B2 (en) | 2016-04-22 | 2024-06-01 | Vaccinex Inc | Integral membrane protein display on poxvirus extracellular enveloped virions |
| KR102449406B1 (ko) | 2016-08-02 | 2022-09-29 | 백시넥스 인코포레이티드 | 백시니아 바이러스/진핵 세포에서 폴리뉴클레오티드 라이브러리를 생산하기 위한 개선된 방법 |
| CN112469735B (zh) * | 2018-09-18 | 2022-11-08 | 天境生物科技(上海)有限公司 | 用于治疗自发性疾病和癌症的抗cxcl13抗体 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US5633149A (en) | 1994-12-07 | 1997-05-27 | Incyte Pharmaceuticals, Inc. | Polynucleotide encoding novel chemokine expressed in inflamed adenoid |
| US6692920B1 (en) | 1994-12-07 | 2004-02-17 | Incyte Corporation | Antibodies to a chemokine expressed in inflamed adenoid |
| WO1996039522A1 (en) | 1995-06-05 | 1996-12-12 | Human Genome Sciences, Inc. | Human chemokine beta-11 and human chemokine alpha-1 |
| WO1998011226A2 (en) | 1996-09-10 | 1998-03-19 | Schering Corporation | Mammalian chemokines, related reagents |
| US6852508B1 (en) | 1997-02-28 | 2005-02-08 | Genetics Institute, Llc | Chemokine with amino-terminal modifications |
| US6110695A (en) | 1997-12-02 | 2000-08-29 | The Regents Of The University Of California | Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1 |
| US6723538B2 (en) | 1999-03-11 | 2004-04-20 | Micromet Ag | Bispecific antibody and chemokine receptor constructs |
| EP1268554A2 (de) | 2000-03-31 | 2003-01-02 | IPF Pharmaceuticals GmbH | Diagnostik- und arzneimittel zur untersuchung des zelloberflächenproteoms von tumor- und entzündungszellen sowie zur behandlung von tumorerkrankungen und entzündlichen erkrankungen vorzugsweise mit hilfe einer spezifischen chemokinrezeptor-analyse und der chemokinrezeptor-ligand-interaktion |
| GB2361003A (en) | 2000-04-07 | 2001-10-10 | Astrazeneca Ab | Novel compounds |
| US7052676B2 (en) | 2000-09-26 | 2006-05-30 | The Regents Of The University Of Michigan | Methods for inhibition of HIV replication using a small molecule inhibitor |
| JP2004517078A (ja) | 2000-12-01 | 2004-06-10 | シェーリング コーポレイション | 哺乳動物遺伝子および関連試薬の使用 |
| US6818406B2 (en) | 2001-03-23 | 2004-11-16 | Mayo Foundation For Medical Education And Research | Rheumatoid arthritis markers |
| US7442512B2 (en) | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| US7413866B2 (en) | 2001-11-30 | 2008-08-19 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| DE60334453D1 (de) | 2002-05-30 | 2010-11-18 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| US20070185017A1 (en) | 2002-10-29 | 2007-08-09 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US7919083B2 (en) | 2002-11-15 | 2011-04-05 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
| AU2003294290A1 (en) | 2002-11-15 | 2004-06-15 | Morehouse School Of Medicine | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation. |
| EP1572116A4 (en) | 2002-11-26 | 2007-12-12 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
| EP1613657A2 (en) | 2003-03-28 | 2006-01-11 | Centocor, Inc. | Anti-amyloid antibodies, compositions, methods and uses |
| AU2005243730B2 (en) | 2004-04-12 | 2010-05-27 | Genvec, Inc. | Method of using adenoviral vectors to induce an immune response |
| CA2501422C (en) | 2004-04-29 | 2014-08-12 | University Of Rochester | Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease |
| CN1842540B (zh) | 2004-07-09 | 2012-07-04 | 中外制药株式会社 | 抗-磷脂酰肌醇蛋白聚糖3抗体 |
| BRPI0518994A2 (pt) | 2004-12-31 | 2008-12-02 | Biogen Idec Inc | anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas |
| EP3479844B1 (en) | 2005-04-15 | 2023-11-22 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| WO2006117910A1 (ja) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| WO2007064911A1 (en) | 2005-12-02 | 2007-06-07 | Biogen Idec Inc. | Anti-mouse cd20 antibodies and uses thereof |
| GB0607774D0 (en) | 2006-04-20 | 2006-05-31 | Renovo Group Plc | Medicaments |
| WO2007124414A2 (en) | 2006-04-21 | 2007-11-01 | Centocor, Inc. | Cxcl13 antagonists and their use for the treatment of inflammatory diseases |
| US20080227704A1 (en) | 2006-12-21 | 2008-09-18 | Kamens Joanne S | CXCL13 binding proteins |
| US20080199481A1 (en) | 2007-02-21 | 2008-08-21 | Astrazeneca Ab | Compounds |
| WO2008121940A1 (en) | 2007-03-30 | 2008-10-09 | Centocor, Inc. | Cxcl13 antagonists and their use for the treatment of inflammatory diseases |
| US20110300167A1 (en) | 2008-11-04 | 2011-12-08 | Mcmurry Thomas J | Cxcr5 receptor compounds |
| AU2011295902B2 (en) | 2010-09-02 | 2014-12-04 | Vaccinex, Inc. | Anti-CXCL13 antibodies and methods of using the same |
| US20130310582A1 (en) * | 2011-02-04 | 2013-11-21 | Dow Global Technologies Llc | Process for removing iron ions from an organic stream |
| CN104114187A (zh) | 2011-12-28 | 2014-10-22 | 诺沃姆德治疗公司 | 去糖基化的人类抗体、其融合蛋白质及用途 |
| NZ629828A (en) | 2012-03-02 | 2017-05-26 | Vaccinex Inc | Methods for the treatment of b cell-mediated inflammatory diseases |
| BR112015021964A2 (pt) | 2013-03-08 | 2017-08-29 | Vaccinex Inc | Anticorpo isolado ou um fragmento ligante de antígenos do mesmo que se liga especificamente a cxcl13, composição e seus usos |
-
2014
- 2014-01-31 EP EP14704507.4A patent/EP2951204B1/en active Active
- 2014-01-31 CA CA2899344A patent/CA2899344C/en active Active
- 2014-01-31 WO PCT/US2014/014107 patent/WO2014121053A1/en not_active Ceased
- 2014-01-31 NZ NZ710744A patent/NZ710744A/en unknown
- 2014-01-31 US US14/765,162 patent/US9790271B2/en active Active
- 2014-01-31 KR KR1020157023489A patent/KR102176962B1/ko active Active
- 2014-01-31 JP JP2015556164A patent/JP6363623B2/ja active Active
- 2014-01-31 CN CN201480012412.5A patent/CN105408355A/zh active Pending
- 2014-01-31 AU AU2014212206A patent/AU2014212206B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014212206B2 (en) | 2018-10-18 |
| KR20150113135A (ko) | 2015-10-07 |
| AU2014212206A1 (en) | 2015-08-20 |
| EP2951204A1 (en) | 2015-12-09 |
| CN105408355A (zh) | 2016-03-16 |
| KR102176962B1 (ko) | 2020-11-10 |
| CA2899344A1 (en) | 2014-08-07 |
| JP6363623B2 (ja) | 2018-07-25 |
| US9790271B2 (en) | 2017-10-17 |
| JP2016507524A (ja) | 2016-03-10 |
| EP2951204B1 (en) | 2019-05-22 |
| US20150368332A1 (en) | 2015-12-24 |
| CA2899344C (en) | 2022-11-08 |
| WO2014121053A1 (en) | 2014-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ710744A (en) | Methods for increasing immunoglobulin a levels | |
| TN2015000050A1 (en) | Methods of treating a tauopathy | |
| EP3702372A3 (en) | Anti-cd40 human antibodies | |
| TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
| SG10201804338PA (en) | Anti-fcrh5 antibodies | |
| WO2014083438A3 (en) | Nitric oxide increasing nutritional supplements and methods | |
| NZ733055A (en) | Anti-c10orf54 antibodies and uses thereof | |
| PH12014500904B1 (en) | Antibody formulations and methods | |
| PH12015501954A1 (en) | Anti-b7-h4 antibodies and immunoconjugates | |
| MX2015014500A (es) | Terapia de combinacion de anticuerpos contra csf-1r y agonista de tlr9. | |
| MX2019015604A (es) | Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia. | |
| UY34582A (es) | Anticuerpos anti-cxcr3 | |
| WO2014108484A3 (en) | Combination therapy of anti-her3 and anti-her2 antibodies | |
| MY173304A (en) | Induction of immune tolerance using methotrexate | |
| PH12015501588B1 (en) | Compounds and methods for treating bacterial infections | |
| MX2016004802A (es) | Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso. | |
| EA201692554A1 (ru) | Менингококковые вакцины | |
| EA201691502A1 (ru) | Мутантные стафилококковые антигены | |
| GB2497453A (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
| MX2015010023A (es) | Anticuerpos anti-cd83 y su uso. | |
| WO2014155259A3 (en) | Process for preparation of rivaroxaban | |
| EA201690378A1 (ru) | Вакцинные композиции против наркотической зависимости | |
| WO2014140833A3 (en) | Methods for differentiating between active and latent tuberculosis disease | |
| UA84186U (ru) | Способ лечения больных с неалкогольным стеатогепатитом после перенесенного инфекционного мононуклеоза | |
| UA89485U (ru) | Способ усиления иммунного ответа мимикринами из бактерий при вакцинации против вирусных и некоторых бактериальных инфекций |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JAN 2022 BY COMPUTER PACKAGES INC Effective date: 20201231 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JAN 2023 BY COMPUTER PACKAGES INC Effective date: 20211230 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JAN 2024 BY COMPUTER PACKAGES INC Effective date: 20221230 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JAN 2025 BY COMPUTER PACKAGES INC Effective date: 20231230 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JAN 2026 BY COMPUTER PACKAGES INC Effective date: 20241230 |